Evidence map›Paper›PMID 39298998›Full record

ArticleVaccine2024

T cell inducing vaccine against cytomegalovirus immediate early 1 (IE1) protein provides high level cross strain protection against congenital CMV.

K Yeon Choi, Nadia El-Hamdi, Alistair McGregor

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

K Yeon ChoiDepartment of Microbial Pathogenesis & Immunology, Texas A&M University, Health Science Center, College of Medicine, Bryan, TX, USA.
Nadia El-HamdiDepartment of Microbial Pathogenesis & Immunology, Texas A&M University, Health Science Center, College of Medicine, Bryan, TX, USA.
Alistair McGregorDepartment of Microbial Pathogenesis & Immunology, Texas A&M University, Health Science Center, College of Medicine, Bryan, TX, USA. Electronic address: mcgalistair2013@tamu.edu.

Funding

Development of a universal DISC vaccine strategy against congenital cytomegalovirusR01AI155561 · NIAID · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI MCGREGOR, ALISTAIR · 2021 to 2025
$3.3M
CMV pentameric complex based vaccine strategies for prevention of congenital CMVR01HD090065 · NICHD · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI MCGREGOR, ALISTAIR · 2017 to 2021
$1.5M
Placental trophoblast infection and TLR mediated response to congenital CMVR01AI100933 · NIAID · UNIVERSITY OF MINNESOTA · PI MCGREGOR, ALISTAIR · 2012 to 2015
$1.5M
Development of an effective DISC vaccine strategy against congenital CMVR01AI098984 · NIAID · UNIVERSITY OF MINNESOTA · PI MCGREGOR, ALISTAIR · 2012 to 2015
$1.4M
NIAID NIH HHS R01 AI098984NIAID NIH HHS R01 AI100933NIAID NIH HHS R01 AI155561NICHD NIH HHS R01 HD090065
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) is a leading cause of congenital disease resulting in cognitive impairment and deafness in newborns. Multiple strains of HCMV enable re-infection and convalescent immunity does not protect against risk of congenital CMV (cCMV). Consequently, a cross strain protective CMV vaccine is a high priority. The guinea pig is the only small animal model for cCMV and species specific guinea pig cytomegalovirus (GPCMV) encodes homolog HCMV viral proteins making it suitable for vaccine studies. Neutralizing antibodies against viral entry glycoprotein complexes and cell free virus are insufficient for complete protection because highly cell associated virus enables evasion. CMV T-cell antigens are important in HCMV convalescent immunity and potentially in reducing the risk of cCMV. Immediate early protein IE1 is essential to HCMV and a T-cell target in humans. In this study, a recombinant defective adenovirus encoding GPCMV IE1 (AdIE1) was evaluated in a preclinical vaccine study. AdIE1 vaccinated animals evoked a T-cell response in a guinea pig IFNγ ELISPOT assay to IE1 (GP123). Vaccinated animals exhibited protection against subcutaneous challenge by GPCMV prototype strain (22122) with viral load substantially reduced compared to the unvaccinated control group and previous Ad based vaccine study against viral pp65 tegument protein. In a vaccine study against cCMV, dams were challenged mid-pregnancy with dual wild type virus strains (22122 and clinical strain TAMYC). At birth, pups were evaluated for viral load in target organs. AdIE1 vaccine had high efficacy against cCMV with GPCMV pup transmission reduced from 92% in the litters of the unvaccinated control group of dams to 23% in the vaccine group resulting in an absence of virus or statistically significant reduction in viral load in pup organs. Overall, IE1 is a more protective T-cell antigen than previously studied pp65 providing cross strain immunity against cCMV in this preclinical model.

Indexed as

Cytomegalovirus InfectionsCytomegalovirus VaccinesImmediate-Early ProteinsT-LymphocytesAnimalsAntibodies, ViralCross ProtectionCytomegalovirusDisease Models, AnimalFemaleGuinea PigsInterferon-gammaAntibodies, ViralCytomegalovirus VaccinesIE1 protein, cytomegalovirusImmediate-Early ProteinsInterferon-gammaCMV animal modelCMV vaccineCongenital CMVCytomegalovirusIE1T cell target

Identifiers

PMID39298998
PMCPMC12206489

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.